2024 Onsite Industry Guide - 19

PM BREAK
LUNCH BREAK
Epidemiologic Trends in Adult Invasive Pneumococcal
Disease and Unmet Needs
Supported by: Merck
3:45 - 4:30 p.m. * Theater 1Register Now
Learning Objectives:
» Raise awareness about ongoing risk and severity of
pneumococcal disease in adult populations
» Highlight epidemiology and prevalent serotypes driving
adult pneumococcal disease
» Discuss the clinical and public health importance of
adult pneumococcal disease
Harish Moorjani, MD ∙ New York, NY
FRIDAY, APRIL 19
MORNING BREAK
Closing the CRC Screening Gaps: Integrating
Screening Protocols, Improving Participation
Supported by: Exact Sciences
10:15 - 11:00 a.m. * Theater 1Register Now
Why does colorectal cancer (CRC) remain the most
preventable yet least prevented cancer in the US? A
look at CRC screening gaps, the importance of support
and multi-modality protocols that help address screening
barriers. This presentation includes insight into follow-up
colonoscopies after positive mt-sDNA test results.
David H. Johnson, MD ∙ Coeur d'Alene, ID
Angela M. Nicholas, MD, FAAFP ∙ North Wales, PA
Unlock the Potential of FreeStyle Libre Systems to
Empower Patients & Providers
Supported by: Abbott Diabetes Care
10:15 - 11:00 a.m. * Theater 2Register Now
Join us for an engaging session about the invaluable
insights CGM provides to both patients and providers to
make data-driven adjustments to therapy and lifestyle
for optimal patient outcomes. This program will review
new clinical evidence, compelling patient case studies,
and discuss best practices for seamless integration into
practice workflows.
Anila Bindal, MD * Alameda, CA
Bhakti Paul, MD, MPH * Raleigh, NC
Natalie J. Bellini, DNP, FNP-BC, BC-ADM * Cleveland, OH
Dexcom Real-Time CGM: A PRIMARY Prescription for
Type 2 Diabetes
Supported by: Dexcom
12:30 - 1:15 p.m. * Theater 1Register Now
Join the conversation as we delve into why the Dexcom
G7 stands out as a primary prescription for managing
diabetes. Discover the advantages of early adoption,
user-friendly simplicity and the performance data
provided by Dexcom RT-CGM.
Thomas Grace, MD, CDCES ∙ Findlay, OH
A Hospitalist's Perspective on the Treatment of
Inpatients with COVID-19
Supported by: Gilead Sciences, Inc.
12:30 - 1:15 p.m. * Theater 2egister Now
Join us to learn more as an expert in COVID-19 shares
key data and clinical insights on treatment options today.
Alpesh Amin, MD, MBA ∙ Irvine, CA
DISCOVER THE IMPACT OF GEMTESA: A Selective
β3-Adrenergic Agonist for Effective OAB Treatment
Supported by: Sumitomo Pharma
12:30 - 1:15 p.m. * Theater 3egister Now
GEMTESA is a β3-adrenergic agonist indicated for the
treatment of overactive bladder (OAB) with symptoms of urge
urinary incontinence, urgency, and urinary frequency in adults.
Matt T. Rosenberg, MD ∙ Jackson, MI
PM BREAK
Advancing Cancer Screening: Adding Multi-Cancer
Early Detection Testing in Clinical Practice
Supported by: GRAIL, LLC
3:45 - 4:30 p.m. * Theater 2gister Now
Currently, only five cancers have recommended
screening. It is important to find deadly cancers before
they become symptomatic. The Galleri test is a simple
blood draw used in addition to current single-cancer
screenings. Learn about the Galleri test and how it is
being used in practice today.
Eric Klein, MD, PhD ∙ Menlo Park, CA
Geoffrey M. Burns, MD, FAACP ∙ Wellesley Hills, MA
Innovation Theater presentations are independently organized and are not an official part of the Internal Medicine Meeting 2024 Education Program.
ONSITE INDUSTRY GUIDE |
Internal Medical Meeting 2024
19

2024 Onsite Industry Guide

Table of Contents for the Digital Edition of 2024 Onsite Industry Guide